Stockscreener 앱 받기
15.05
3.79%
0.55
전일 마감가:
$14.50
열려 있는:
$14.58
하루 거래량:
118.49K
Relative Volume:
0.54
시가총액:
$501.28M
수익:
$65.42M
순이익/손실:
$-32.96M
주가수익비율:
-11.85
EPS:
-1.27
순현금흐름:
$-19.87M
1주 성능:
-3.96%
1개월 성능:
-6.70%
6개월 성능:
+61.48%
1년 성능:
+24.48%
1일 변동 폭
$14.57
$15.32
1주일 범위
$14.02
$15.97
52주 변동 폭
$7.5625
$18.98
뉴로페이스 Stock (NPCE) Company Profile
명칭
Neuropace Inc
전화
(650) 237-2700
주소
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Compare NPCE vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
15.05 | 482.96M | 65.42M | -32.96M | -19.87M | -1.27 |
|
ABT
Abbott Laboratories
|
112.68 | 193.83B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
366.05 | 140.01B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
99.49 | 129.33B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
74.73 | 109.92B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
75.87 | 44.36B | 6.07B | 1.06B | 799.60M | 1.8527 |
뉴로페이스 Stock (NPCE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-28 | 개시 | H.C. Wainwright | Buy |
| 2025-01-21 | 개시 | UBS | Buy |
| 2024-03-14 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | 개시 | Leerink Partners | Outperform |
| 2023-11-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-08-24 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | 개시 | Lake Street | Buy |
| 2022-04-06 | 개시 | Wolfe Research | Outperform |
| 2022-01-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | 개시 | Robert W. Baird | Outperform |
| 2021-05-17 | 개시 | JP Morgan | Overweight |
| 2021-05-17 | 개시 | Morgan Stanley | Overweight |
| 2021-05-17 | 개시 | SVB Leerink | Outperform |
| 2021-05-17 | 개시 | Wells Fargo | Overweight |
모두보기
뉴로페이스 주식(NPCE)의 최신 뉴스
Neuropace, Inc. (NPCE) Stock Analysis: A 34% Potential Upside Sparks Investor Interest - DirectorsTalk Interviews
Essex Investment Management Co. LLC Raises Holdings in NeuroPace, Inc. $NPCE - MarketBeat
How Does NeuroPace's Personalized Technology Transform Seizure Control - Kalkine Media
NeuroPace, Inc. (NASDAQ:NPCE) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Aug Intraday: Is NeuroPace Inc a stock for growth or value investorsBond Market & High Conviction Buy Zone Alerts - baoquankhu1.vn
Neuropace, Inc. (NPCE) Stock Analysis: Exploring the 25.89% Potential Upside and Analyst Optimism - DirectorsTalk Interviews
Trading Systems Reacting to (NPCE) Volatility - Stock Traders Daily
How NeuroPace (NPCE) Analysts Are Quietly Rewriting The Story Behind The Stock - Yahoo Finance
NeuroPace stock price target raised to $20 from $19 at Leerink Partners By Investing.com - Investing.com Australia
NeuroPace stock price target raised to $20 from $19 at Leerink Partners - Investing.com Nigeria
Neuropace, Inc. (NPCE) Investor Outlook: A Medical Device Innovator with 26% Potential Upside - DirectorsTalk Interviews
FY2025 EPS Estimates for NeuroPace Lifted by HC Wainwright - MarketBeat
NeuroPace stock price target raised to $19 from $18 at H.C. Wainwright - Investing.com Nigeria
NeuroPace stock price target raised to $19 from $18 at H.C. Wainwright By Investing.com - Investing.com Canada
Beyond The Numbers: 5 Analysts Discuss NeuroPace Stock - Benzinga
NeuroPace price target raised to $19 from $18 at H.C. Wainwright - TipRanks
Juniper Biomedical Appoints Frank Fischer To Board - citybiz
CORRECTING and REPLACING Juniper Biomedical Wins Neuromod Prize and Welcomes Frank Fischer to Board of Directors - The AI Journal
NeuroPace, Inc. (NASDAQ:NPCE) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
NeuroPace, Inc. (NASDAQ:NPCE) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
NeuroPace sees Q4 revenue of about $26.6M - MSN
NeuroPace stock rises as UBS reiterates Buy rating after strong Q4 revenue - Investing.com Australia
NeuroPace stock rises as UBS reiterates Buy rating after strong Q4 revenue By Investing.com - Investing.com South Africa
US-based NeuroPace revenue expected to grow 24% in Q4 2025 - Medical Buyer
Profit Recap: Will NeuroPace Inc stock benefit from M AWeekly Profit Summary & Growth Focused Stock Pick Reports - baoquankhu1.vn
NeuroPace reports 25% revenue growth for 2025, projects steady growth By Investing.com - Investing.com Nigeria
NeuroPace Reports Preliminary Q4, 2025 Revenue; Sets 2026 Guidance - marketscreener.com
NeuroPace (NASDAQ:NPCE) Shares Gap UpShould You Buy? - MarketBeat
NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook - Investing News Network
NeuroPace, Inc. Provides Earnings Guidance for the First Quarter and Full Year of Fiscal 2026 - marketscreener.com
NeuroPace reports 25% revenue growth for 2025, projects steady growth - Investing.com
NeuroPace (NASDAQ:NPCE) and Envoy Medical (NASDAQ:COCH) Critical Comparison - Defense World
NeuroPace (NASDAQ:NPCE) Stock Price Down 4.4% – What’s Next? - Defense World
Neurological Implants Market to Reach USD 12.39 Billion by 2031 | - openPR.com
Neuropace, Inc. (NPCE) Investor Outlook: Exploring the 13.5% Potential Upside in Medical Devices - DirectorsTalk Interviews
NeuroPace (NASDAQ:NPCE) Shares Down 4.4%Should You Sell? - MarketBeat
How resilient is NeuroPace Inc. stock in market downturnsDay Trade & Safe Investment Capital Preservation Plans - ulpravda.ru
When Will NeuroPace, Inc. (NASDAQ:NPCE) Turn A Profit? - 富途资讯
NeuroPace (NASDAQ:NPCE) Has Debt But No Earnings; Should You Worry? - simplywall.st
Financial Review: Vicarious Surgical (NYSE:RBOT) vs. NeuroPace (NASDAQ:NPCE) - Defense World
How NeuroPace Inc. stock performs in rate cut cyclesJuly 2025 Breakouts & Risk Managed Investment Strategies - Улправда
Is NeuroPace Inc. stock oversold or undervaluedMarket Activity Recap & Stepwise Entry/Exit Trade Alerts - ulpravda.ru
Will NeuroPace Inc. stock benefit from green energy trendsWatch List & High Conviction Investment Ideas - ulpravda.ru
Why NeuroPace Inc. stock remains undervaluedGlobal Market Influence & Low Risk Capital Appreciation - Улправда
NeuroPace (NASDAQ:NPCE) Sees Strong Trading VolumeHere's Why - MarketBeat
NeuroPace stock dips after pricing $65M share offering - MSN
Can NeuroPace Inc. stock deliver sustainable ROE2026 world cup usa national team third place match playmakers high defensive line expert forecast breakdown - ulpravda.ru
UBS sees upside for NeuroPace shares with 22% CAGR and market expansion drivers - MSN
User | bigspringherald.comNeuropace, Inc.Common Stock (Nasdaq:NPCE) Stock Quote - FinancialContent
UBS Initiates Coverage of NeuroPace (NPCE) with Buy Recommendation - MSN
Responsive Playbooks and the NPCE Inflection - Stock Traders Daily
뉴로페이스 (NPCE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
뉴로페이스 주식 (NPCE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 10% Owner |
May 14 '25 |
Sale |
15.85 |
168,136 |
2,665,333 |
3,238,199 |
| Morrell Martha | CHIEF MEDICAL OFFICER |
Feb 21 '25 |
Sale |
13.72 |
78,334 |
1,074,844 |
81,993 |
| KCK LTD. | 10% Owner |
Feb 20 '25 |
Sale |
9.40 |
5,270,845 |
49,545,943 |
0 |
1.33%
0.51%
자본화:
|
볼륨(24시간):